The difficult balance between thrombosis and bleeding after transcatheter aortic valve replacement: A translational review.
Animals
Anticoagulants
/ administration & dosage
Aortic Valve
/ surgery
Aortic Valve Stenosis
/ mortality
Clinical Decision-Making
Fibrinolytic Agents
/ administration & dosage
Heart Valve Prosthesis
Humans
Postoperative Hemorrhage
/ etiology
Risk Assessment
Risk Factors
Thrombosis
/ etiology
Time Factors
Transcatheter Aortic Valve Replacement
/ adverse effects
Translational Research, Biomedical
Treatment Outcome
Bleeding
Physiopathologie
Physiopathology
Remplacement valvulaire aortique percutané
Saignement
Thrombose
Thrombosis
Transcatheter aortic valve replacement
Journal
Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
26
07
2019
revised:
26
11
2019
accepted:
02
12
2019
pubmed:
15
2
2020
medline:
7
7
2020
entrez:
15
2
2020
Statut:
ppublish
Résumé
Transcatheter aortic valve replacement (TAVR) has emerged as the treatment of choice for patients with severe aortic stenosis deemed at high or intermediate risk for cardiac surgery. In light of the latest literature advances, TAVR will undoubtedly concern a growing number of patients because of the progressive extension of its indications. Whereas significant efforts have been made to reduce the burden of periprocedural complications, TAVR still exposes patients to a sizeable number of adverse outcomes, including thrombotic and bleeding events. Although contradictory, these two phenomena are closely related to pathophysiological processes inherent to flow disturbances induced by aortic stenosis itself, but also to a complex interaction between bioprosthetic valves and native tissues in frail patients clustering various co-morbidities. Reinforcing this paradigm, multiple TAVR studies have emphasized the view that both thrombosis and bleeding events have a deleterious effect on patient outcomes. Therefore, we sought to perform a comprehensive translational review of the current literature addressing the pathophysiological mechanisms leading to thrombosis and bleeding after TAVR, and underline innovative strategies aimed at reducing these complications.
Identifiants
pubmed: 32057662
pii: S1875-2136(20)30019-X
doi: 10.1016/j.acvd.2019.12.003
pii:
doi:
Substances chimiques
Anticoagulants
0
Fibrinolytic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
263-275Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.